Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer
Inclusion Criteria
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have histologically proven stage IIB (T3N0M0 only), IIIA (T2N1M0), IIIB (T4N0M0), or IIIC (T3N1M0, T4N1M0) invasive squamous cell carcinoma of the anus or anorectum, according to the American Joint Committee on Cancer (AJCC) 8th edition; this may include tumors of non-keratinizing histology such as basaloid, transitional cell, or cloacogenic histology; individuals with squamous cell carcinoma of the anal margin are eligible if there is evidence of extension of the primary tumor into the anal canal
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must have hemoglobin levels of > 9 g/dL (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient must have a platelet count of > 100,000/mm^3 (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient’s absolute neutrophil count (ANC) level must be > 1500/mm^3 (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Serum creatinine must be =< 1.5 X upper limit of normal (ULN) (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Total bilirubin must be < 2 X ULN (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X institutional upper limit of normal (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Albumin >= 3.0 g/dL (within 2 weeks prior to registration)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients known to be human immunodeficiency virus (HIV)+ are permitted; patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are eligible, and in addition: * Participants must be purified protein derivative (PPD) negative; alternatively, the QuantiFERON-tuberculosis (TB) Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 20 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment * No history of acquired immune deficiency syndrome (AIDS)-related complications within past year other than a history of low CD4+ T-cell count > 200/mm^3 prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to chemoradiotherapy and should not be used as an exclusion criterion if low * Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the anal cancer * Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment * Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative; * NOTE: HIV testing is not required for eligibility
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: For patients registering prior to start of chemoradiotherapy, baseline scans must have been completed within 4 weeks prior to registration
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Women of child bearing potential and sexually active males must use accepted and effective method(s) of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 5 months after the last dose of nivolumab (for female patients) and for at least 7 months after the last dose of nivolumab (for male patients)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Any surgery must have been completed >= 4 weeks prior to starting study treatment
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 monoclonal antibody)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No patients with immunodeficiency or receiving systemic steroid therapy equivalent to > 10 mg prednisone per day or any other form of immunosuppressive therapy within 7 days prior to Step 1 registration; topical corticosteroid or occasional inhaled corticosteroids are allowed
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: No live vaccines within 30 days prior to registration; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed * NOTE: no live vaccines may be administered while participating in the trial
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Previously irradiated patients (Arm S) must have received radiation per National Comprehensive Cancer Network guidelines; radiation therapy delivered on protocol (Arm T) will be reviewed
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients will be registered within 63 days following completion of standard chemoradiation for anal cancer; standard chemoradiation therapy is as defined
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have histologically proven stage IIB (T3N0M0 only), IIIA (T2N1M0), IIIB (T4N0M0), or IIIC (T3N1M0, T4N1M0) invasive squamous cell carcinoma of the anus or anorectum, according to the AJCC 8th edition; this may include tumors of non-keratinizing histology such as basaloid, transitional cell, or cloacogenic histology; individuals with squamous cell carcinoma of the anal margin are eligible if there is evidence of extension of the primary tumor into the anal canal
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have received at least 54 gray (Gy) of radiation to the PTVp (primary) and 45 Gy to PTVn (elective nodal region) for the treatment of the anal cancer
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have ECOG performance status of 0-2
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must have hemoglobin levels of > 10 g/dL (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have a platelet count of > 100,000/mm^3 (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient’s ANC level must be > 1500/mm^3 (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Serum creatinine must be =< 1.5 X ULN (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Total bilirubin must be < 2 X ULN (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: AST (SGOT)/ALT (SGPT) =< 2.5 X institutional upper limit of normal (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Albumin >= 3.0 g/dL (within 2 weeks prior to registration)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients known to be human immunodeficiency virus (HIV)+ patients with CD4 > 200 and serum HIV viral load of < 200 copies/mm^3 are eligible; in addition: * Participants must be PPD negative; alternatively, the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Limited, Carnegie, Australia) can be used; an individual is considered positive for M. tuberculosis infection if the IFN-gamma response to TB antigens is above the test cut-off (after subtracting the background IFN-gamma response in the negative control); the result must be obtained within 20 weeks prior to enrollment; PPD positive (or Quantiferon assay positive) participants are permitted if prophylaxis has been completed prior to enrollment; NOTE: If patient completed chemoradiation on Step 1, PPD testing does not need to be performed again * No history of AIDS-related complications within past year other than a history of low CD4+ T-cell count > 200/mm^3 prior to initiation of combination antiretroviral therapy; on study CD4+ T-cell count may not be informative due to chemoradiotherapy should not be used as an exclusion criterion if low * Patient must be healthy on the basis of HIV disease with high likelihood of near normal life span were it not for the anal cancer * Participants MUST receive appropriate care and treatment for HIV infection, including antiretroviral medications when clinically indicated, and should be under the care of a physician experienced in HIV management; participants will be eligible regardless of antiretroviral medication (including no antiretroviral medication) provided there is no intention to initiate therapy or the regimen has been stable for at least 4 weeks with no intention to change the regimen within 12 weeks following enrollment * Patient must have =< grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative) * NOTE: HIV testing is not required for eligibility
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Scans done within 4 weeks of randomization to Step 2
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must have recovered from all toxicities associated with chemoradiotherapy for anal cancer, to grade =< 1 with the exception of alopecia
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Women of child bearing potential and sexually active males must use accepted and effective method(s) of contraception and/or abstain from sexual intercourse while on protocol treatment and for at least 5 months after the last dose of nivolumab (for female patients) and for at least 7 months after the last dose of nivolumab (for male patients)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No prior treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 monoclonal antibody)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No patients with immunodeficiency or receiving systemic steroid therapy equivalent to > 10 mg prednisone per day or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication; topical corticosteroid or occasional inhaled corticosteroids are allowed
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: No live vaccines within 30 days prior to the first dose of trial treatment and while participating in the trial; examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine; seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist) are live attenuated vaccines and are not allowed
Exclusion Criteria
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: For patients registering to Arm T, patients must not have received prior chemoradiotherapy for anal cancer
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients with an allogenic bone marrow/stem, cell or solid organ transplant are excluded
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Women MUST NOT be pregnant or breast-feeding due to the potential teratogenic harm or abortifacient effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used; all patients must also not expect to conceive or father children from study registration and throughout their time on study treatment; for female patients this must continue until at least 5 months after the last dose of nivolumab and for male patients until at least 7 months after the last dose of nivolumab; all females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients will be excluded if they have a T1 or M1, and T2N0 cancer
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must not have had prior potentially curative surgery (abdominal, peritoneal resection) for carcinoma of the anus
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Participants may not be receiving any other standard anti-cancer therapy or experimental agent concurrently with the study drugs
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Individuals with a history of a different malignancy are ineligible except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patient must not have active autoimmune disease in the past 2 years * NOTE: This does not include patients with autoimmune disease controlled by medication, such as hypothyroidism; this eligibility includes only patients with endocrine disease controlled by hormone replacement, e.g. hypothyroid, adrenal insufficiency, or diabetes mellitus (DM)
- REGISTRATION TO STEP 1 ELIGIBILITY CRITERIA: Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients with an allogenic bone marrow/stem, cell or solid organ transplant are excluded
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Women MUST NOT be pregnant or breast-feeding due to the potential teratogenic harm or abortifacient effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used; all patients must also not expect to conceive or father children from study registration and throughout their time on study treatment; for female patients this must continue until at least 5 months after the last dose of nivolumab and for male patients until at least 7 months after the last dose of nivolumab; all females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy, or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have had prior potentially curative surgery (abdominal, peritoneal resection) for carcinoma of the anus
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Participants may not be receiving any other standard anti-cancer therapy or experimental agent concurrently with the study drugs
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Individuals with a history of a different malignancy are ineligible except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence; individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patient must not have active autoimmune disease that has required systemic treatment in past 2 years
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have known interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity
- REGISTRATION TO STEP 2 ELIGIBILITY CRITERIA: Patients must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to nivolumab
Alabama
Birmingham
Alaska
Anchorage
Fairbanks
Arizona
Goodyear
Kingman
Phoenix
Scottsdale
Arkansas
Ft. Smith
Hot Springs
Jonesboro
Little Rock
California
Anaheim
Antioch
Arroyo Grande
Auburn
Baldwin Park
Bellflower
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Chico
Clovis
Davis
Dublin
Fontana
Fremont
Fresno
Harbor City
Irvine
La Jolla
Los Angeles
Marysville
Modesto
Mountain View
Newport Beach
Novato
Oakland
Ontario
Orange
Palo Alto
Panorama City
Pasadena
Rancho Cordova
Rancho Mirage
Redwood City
Richmond
Riverside
Rohnert Park
Roseville
Sacramento
San Diego
San Francisco
San Jose
San Leandro
San Marcos
San Mateo
San Rafael
Santa Clara
Santa Cruz
Santa Maria
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Vacaville
Vallejo
Walnut Creek
Woodland Hills
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Golden
Grand Junction
Greeley
Lafayette
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Delaware
Frankford
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Altamonte Springs
Aventura
Celebration
Coral Gables
Fort Lauderdale
Gainesville
Hollywood
Jacksonville
Kissimmee
Miami
Miami Beach
Orlando
Pembroke Pines
Pensacola
Weston
Winter Park
Georgia
Atlanta
Decatur
Johns Creek
Savannah
Hawaii
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Burr Ridge
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Dixon
Effingham
Eureka
Evanston
Galesburg
Glenview
Highland Park
Kewanee
Lake Forest
Macomb
Mattoon
Maywood
Melrose Park
Mount Vernon
O'Fallon
Orland Park
Ottawa
Pekin
Peoria
Peru
Princeton
Springfield
Swansea
Urbana
Yorkville
Indiana
Carmel
Indianapolis
Michigan City
Mooresville
Terre Haute
Iowa
Bettendorf
Clive
Council Bluffs
Creston
Des Moines
Fort Dodge
Iowa City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Fairway
Independence
Kingman
Lawrence
Liberal
Manhattan
McPherson
Newton
Olathe
Parsons
Pittsburg
Pratt
Salina
Topeka
Wellington
Westwood
Wichita
Winfield
Kentucky
Bardstown
Corbin
Lexington
London
Louisville
Madisonville
Paducah
Shepherdsville
Louisiana
Metairie
New Orleans
Maryland
Baltimore
Massachusetts
Boston
Fitchburg
Springfield
Worcester
Michigan
Ann Arbor
Battle Creek
Bay City
Bloomfield
Brighton
Brownstown
Canton
Caro
Chelsea
Clarkston
Clinton Township
Dearborn
Detroit
East China
Farmington Hills
Flint
Grand Rapids
Grosse Pointe
Grosse Pointe Woods
Jackson
Kalamazoo
Lansing
Lapeer
Livonia
Macomb Township
Marlette
Mount Clemens
Mount Pleasant
Muskegon
Niles
Norton Shores
Novi
Petoskey
Pontiac
Port Huron
Reed City
Rochester Hills
Roseville
Royal Oak
Saginaw
Saint Joseph
Shelby Township
Southfield
Sterling Heights
Tawas City
Traverse City
Troy
Warren
West Bloomfield
West Branch
Wyoming
Ypsilanti
Minnesota
Aitkin
Bemidji
Brainerd
Burnsville
Cambridge
Coon Rapids
Deer River
Detroit Lakes
Duluth
Edina
Fergus Falls
Fosston
Fridley
Hibbing
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Park Rapids
Princeton
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Sandstone
Shakopee
Stillwater
Thief River Falls
Virginia
Waconia
Willmar
Woodbury
Worthington
Wyoming
Mississippi
Grenada
New Albany
Oxford
Southhaven
Missouri
Ballwin
Bonne Terre
Branson
Cape Girardeau
Creve Coeur
Farmington
Jefferson City
Joplin
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Washington
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Papillion
Nevada
Carson City
Henderson
Las Vegas
Pahrump
Reno
New Hampshire
Lebanon
New Jersey
Basking Ridge
Middletown
Montvale
Moorestown
Morristown
Mount Holly
New Brunswick
Summit
Teaneck
Voorhees
New Mexico
Albuquerque
Rio Rancho
New York
Bronx
Buffalo
Commack
Glens Falls
New York
Uniondale
West Harrison
North Carolina
Albemarle
Chapel Hill
Charlotte
Clinton
Elkin
Gastonia
Goldsboro
Hendersonville
Jacksonville
Kenansville
Kinston
Lexington
Monroe
Mount Airy
Raleigh
Richlands
Winston-Salem
North Dakota
Bismarck
Fargo
Jamestown
Minot
Ohio
Beachwood
Belpre
Chardon
Chillicothe
Cincinnati
Cleveland
Columbus
Delaware
Dublin
Elyria
Grove City
Lancaster
Mansfield
Marietta
Marion
Mayfield Heights
Mentor
Middleburg Heights
Mount Vernon
Newark
Parma
Portsmouth
Ravenna
Sandusky
Wadsworth
West Chester
Westerville
Westlake
Zanesville
Oklahoma
Lawton
Oklahoma City
Tulsa
Oregon
Baker City
Bend
Clackamas
Coos Bay
Newberg
Ontario
Portland
Redmond
Pennsylvania
Abington
Allentown
Beaver
Bethlehem
Bryn Mawr
Chadds Ford
Collegeville
Danville
East Stroudsburg
Exton
Greensburg
Harrisburg
Hazleton
Johnstown
Lewisburg
Lewistown
McKeesport
Media
Moon Township
Paoli
Philadelphia
Pittsburgh
Pottsville
Seneca
State College
Uniontown
Washington
West Reading
Wilkes-Barre
Willow Grove
Wynnewood
South Carolina
Boiling Springs
Clinton
Easley
Gaffney
Georgetown
Greenville
Greer
Rock Hill
Seneca
Spartanburg
Union
South Dakota
Sioux Falls
Tennessee
Chattanooga
Collierville
Franklin
Hixson
Memphis
Nashville
Ooltewah
Texas
Bryan
Dallas
Fort Worth
Houston
Richardson
Utah
American Fork
Cedar City
Farmington
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Vermont
Berlin
Burlington
Saint Johnsbury
Virginia
Martinsville
Richmond
South Hill
Washington
Aberdeen
Auburn
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Enumclaw
Everett
Federal Way
Gig Harbor
Issaquah
Kennewick
Lacey
Lakewood
Longview
Port Townsend
Poulsbo
Puyallup
Renton
Seattle
Sedro-Woolley
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yelm
West Virginia
Bridgeport
Charleston
Martinsburg
Morgantown
Parkersburg
Wisconsin
Ashland
Burlington
Eau Claire
Fond Du Lac
Germantown
Grafton
Green Bay
Johnson Creek
Kenosha
La Crosse
Madison
Marinette
Marshfield
Milwaukee
Minocqua
Mukwonago
New Richmond
Oconomowoc
Oshkosh
Racine
Rice Lake
Sheboygan
Stevens Point
Summit
Two Rivers
Waukesha
Wausau
Wauwatosa
West Allis
Weston
Wyoming
Cheyenne
Cody
Sheridan
Alberta
Calgary
British Columbia
Vancouver
Newfoundland
St. John's
Ontario
London
Ottawa
Sault Ste Marie
Toronto
Saskatchewan
Regina
Saskatoon
PRIMARY OBJECTIVE:
I. To evaluate whether therapy with nivolumab following combined modality therapy (CMT) improves disease-free survival (DFS) compared with observation in patients with high risk anal carcinoma.
SECONDARY OBJECTIVES:
I. To compare nivolumab following combined modality therapy (CMT) with observation in patients with high risk anal carcinoma with regard to:
Ia. Objective response rate (complete [CR] and partial [PR]), stable disease and progression.
Ib. Severe toxicity interval.
Ic. Colostomy-free survival.
Id. Overall survival.
Ie. Toxicity.
OUTLINE: Patients who received standard CMT are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 4 weeks for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo observation for up to 6 months.
After completion of study treatment, patients are followed up at 6 weeks, every 3 months for 2 years, and then every 6 months for 3 years.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
ECOG-ACRIN Cancer Research Group
Principal Investigator
Lakshmi Rajdev
- Primary ID EA2165
- Secondary IDs NCI-2017-01347
- Clinicaltrials.gov ID NCT03233711